Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1969318 | Clinical Biochemistry | 2012 | 4 Pages |
ObjectivesPrior to large studies in breast cancer patients, we have sought to establish the normal range of a potential serum biomarker, Amphiregulin, in healthy women and to determine whether sampling during the menstrual cycle influences the detected Amphiregulin levels.Design and methodsSerum Amphiregulin levels were quantified using a commercially available ELISA in 85 normal female donors.ResultsThe range of circulating Amphiregulin was 0–4467 pg/mL. The majority of women had no detectable circulating Amphiregulin (n = 54), and only five women had levels exceeding 500 pg/mL. Serum Amphiregulin levels did not vary significantly during the menstrual cycle (n = 7 women).ConclusionsDetection of circulating Amphiregulin in a significant minority of healthy women suggests that it may not have the specificity necessary for a population screening tool; however its potential utility for monitoring response to treatment or disease progression should be examined in breast cancer cases.
► Detectable serum Amphiregulin levels do not change over multiple freeze–thaw cycles. ► Circulating Amphiregulin was undetectable in 65% of women. ► The range was 0–4467 pg/mL in the study population. ► In women with detectable serum Amphiregulin, the levels did not change during the menstrual cycle.